Extract
The persisting worldwide burden of tuberculosis (TB) is worrisome. In 2018, an estimated 10 million individuals developed TB and 1.45 million infected individuals died [1]. The increase in drug resistance is an important point of concern. Resistance can be acquired by inappropriate drug management, noncompliance and insufficient drug exposure [2, 3]. The last is frequently described for the first-line TB drugs rifampicin and isoniazid due to large interindividual pharmacokinetic variability [3]. Therapeutic drug monitoring (TDM) can be used to verify drug exposure and adjust individual drug dosages if needed [4].
Abstract
Therapeutic drug monitoring using saliva samples is feasible for rifampicin, despite low penetration, but is not feasible for isoniazid, which showed inexplicable highly variable saliva/serum concentration ratios https://bit.ly/2yAS2Jc
Footnotes
This study was registered at Clinicaltrials.gov as NCT03080012.
Conflict of interest: S.H.J. van den Elsen has nothing to disclose.
Conflict of interest: O.W. Akkerman has nothing to disclose.
Conflict of interest: M. Wessels has nothing to disclose.
Conflict of interest: E.M. Jongedijk has nothing to disclose.
Conflict of interest: S. Ghimire has nothing to disclose.
Conflict of interest: T.S. van der Werf has nothing to disclose.
Conflict of interest: M.S. Bolhuis has nothing to disclose.
Conflict of interest: D.J. Touw has nothing to disclose.
Conflict of interest: J-W.C. Alffenaar has nothing to disclose.
- Received March 22, 2020.
- Accepted May 5, 2020.
- Copyright ©ERS 2020
LIBRARY USERS
Log in through your institution
Purchase access
